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Original article
Allergy, Asthma, and Inflammation: Which Inflammatory 
Cell Type Is More Important?
Redwan Moqbel, PhD, FRCPath, and Solomon O. Odemuyiwa, DVM, PhD
a recent review in Allergy, Asthma, and Clinical Immunology suggested that eosinophils play a minor role, if any, in the inflammatory 
spectrum of asthma and allergic inflammation. the article that dealt with mast cells suggested that the presence of these important 
cells within the smooth muscle layer in asthmatic airways renders this cell type primal in asthma and an obvious and important target for 
therapy. this article proposes that in a complex inflammatory milieu characterizing the complex syndromes we call asthma, no single 
cell phenotype is responsible for the condition and thus should be a sole target for therapeutic strategies. Our reductionist approach 
to research in asthma and related conditions has provided us with convincing evidence for multiple roles that immune, inflammatory, 
and structural cell types can play in complex diseases. the next stage in understanding and ameliorating these complex conditions 
is to move away from the simplistic notion of one cell type being more important than another. instead, what is needed is to acquire 
knowledge of intricate and exquisite biological systems that regulate such conditions in both health and disease involving various cell 
types, mediators, pharmacologically active products, their multifaceted capacities, and their   socio-  biological networking.
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strategies targeted at mast cells, rather than eosinophils, may 
be a novel therapeutic option for the control of asthma.
The current article is not an attempt to praise the eosino-
phil and rush to defend its potential role in asthma or to at-
tack or denigrate the role of the mast cell. The aim, instead, 
is to attract attention to the concept of complexity of systems 
and to refute the notion that any given disease, and the even-
tual pathway to its control, may be due to the deleterious 
action of one prominent cell type. In particular, the author 
contended that, in contrast to other cell types, including the 
eosinophils, the presence of mast cells within hypertrophied 
smooth muscle layers in airway tissues in asthmatic patients1,2 
is indicative of the importance of this cell type, as a target for   
therapy.
Eosinophils, Mast Cells, T-  Helper 2–Type Response 
and Allergic Asthma
We owe a debt of gratitude to Paul Ehrlich for first describing 
both the mast cell and the eosinophil.3 Early studies consis-
tently identified an association between these two cell types 
and a number of disease conditions, most of which are now 
known to be biased toward both innate and adaptive T-  helper 
(Th)2-  type response.4 Th2-  type responses are characterized 
by increases in the levels of interleukin (IL)-  4 and other Th2 
cytokines (IL-  5, IL-  9, IL-  13, and IL-  21), activation and expan-
sion of CD4+ Th2 cells, plasma cells secreting IgE, eosinophils, 
basophils, and mast cells, all of which can synthesize and re-
O
ur current understanding of the complex events associ-
ated with the immunobiology of inflammation is pro-
gressively evolving. Research over the last century has pro-
vided an ever-  expanding appreciation of the multifactorial 
and complex nature of the wide spectrum of changes associ-
ated with immunity and inflammation. Numerous players and 
cascades contribute to both up-   and downregulation of the po-
tential function and role of various immunologic, structural, 
and inflammatory cell types and other components in health 
and disease. The article by Bradding in the previous issue of 
this journal argued the case for the mast cell being the key cell 
type in asthma.1 It was suggested that eosinophils, which are 
major orchestrators of the pathophysiological changes seen 
in asthma, could be used as biomarkers of disease phenotype 
and response to therapy. The author, therefore, proposed that 
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ings, Ach binds to M3 receptors on ASM cells; further release 
of Ach is halted through the activity of M2 receptors on cho-
linergic nerve endings, limiting ASM constriction.16 Studies 
in animal models and humans have shown that   eosinophil-   
derived MBP, found in the vicinity of cholinergic nerve end-
ings in asthmatics, inhibits the ability of M2 muscarinic 
  receptors to halt the release of Ach, leading to airway hyperre-
sponsiveness in asthmatics (AHR).17,18 The role of cholinergic 
nerve endings and   eosinophil-  derived MBP in the pathophys-
iology of EB vis-  à-  vis asthma is currently unknown. None-
theless, it is quite instructive to note that the localization of 
mast cells, in ASM cells or eosinophils, around cholinergic 
nerve fibres, in different phenotypes of eosinophilic airway 
diseases, may determine the relative role of each cell type in   
such conditions.
One Cell, One Disease, One Treatment?
Early studies reporting the preponderance of eosinophils in 
allergic asthma and the toxicity of their   granule-  stored me-
diators indicated the need to focus on understanding eo-
sinophil effector function in vitro and in vivo. This resulted 
in focused attention on targeting the eosinophil as a major 
therapeutic strategy for asthma using novel approaches. This 
included anti-eosinophil strategies, which were particularly 
relevant since corticosteroids, choice therapies for asthma, 
were shown to downregulate eosinophil counts in blood, 
sputum, bronchoalveolar lavage (BAL), and airway tissue. 
These changes correlated well with symptom improvement 
and amelioration of disease severity.19 These studies led to 
the discovery of IL-  5 in the 1980s and identification of the 
range of its activities, especially its role as the most crucial 
esoinophil   terminal-  differentiating cytokine.20,21 As a result, 
major pharmaceutical firms invested widely in the area of   IL-  5 
antagonism with the hope of blocking eosinophil influx into 
the airway tissue and the subsequent associated inflammatory 
and damaging sequelae. Animal models, particularly studies 
in monkeys, optimistically anticipated successful targeting of 
a single cell phenotype in a complex disease condition.22 As 
mentioned in the Bradding review , clinical trials with a hu-
manized anti-  IL-  5 monoclonal antibody, mepolizumab, were 
disappointing. Indeed, it was shown that targeting the eosino-
phil is far more complex than blocking its differentiation at 
the level of the bone marrow and blood.23
Following the poor results of mepolizumab, various labo-
ratories sought to understand the reasons behind the appar-
ent failure of this treatment in the management of asthma. To 
start with, the Leckie and colleagues study was regarded to 
have been not only well underpowered to appreciate statistical 
differences in the treatment group but also that the airways of 
lease several types of Th2 cytokines.5 The observed prepon-
derance of eosinophils and mast cells in parasitic helminth in-
fections led to an upsurge in both in vitro and in vivo studies 
examining the capacity of these cells to influence the inflam-
matory milieu associated with these infections in favour of the 
host.6,7 It is now known that T cell–dependent recruitment 
and activation of eosinophils and mast cells are a crucial step 
toward the control of   parasite-  induced granulomas in tissues 
and expulsion of adult worms from the gut.8 It was during the 
1980s that elegant clinical studies pointed to a close statistical 
correlation between airway tissue damage in asthma and the 
activation of eosinophils as manifested by secretion of their 
crystalloid   granule-  stored cationic proteins.9,10 Other stud-
ies also identified mast cell hyperplasia as an important com-
ponent of airway pathology in asthma. Since this discovery, 
both cell types were subjects of extensive studies to determine 
their precise roles in the immunopathology of asthma. Mast 
cells and eosinophils synthesize, store, and release a similar 
profile of Th2 cytokines. However, whereas mast cells store 
and release histamine following activation, eosinophils store 
and   release cationic proteins.11 As previously indicated in the 
Bradding article, mast cell–derived histamine plays a crucial 
role in the induction of bronchial hyperresponsiveness dur-
ing the early phase of asthma.1 Conversely, the late-  phase 
response, seen in some asthmatics, is associated with activa-
tion of eosinophils12; direct instillation of major basic protein 
(MBP), derived from eosinophilic granules, into the lungs 
of monkeys was shown, like mast cell–derived histamine, to 
cause bronchospasm and increased smooth muscle respon-
siveness to methacholine.13
A major argument advanced by Bradding to support 
an “executive” role for mast cells in the pathophysiology of 
asthma is the apparent similarity between the immunopathol-
ogy of asthma and eosinophilic bronchitis (EB) in spite of the 
stark differences in physiological derangement between the 
two conditions.2 Bradding suggested that a major factor in 
asthmatic AHR and airway smooth muscle (ASM) dysfunc-
tion seen in asthma but not in EB is likely due to the presence 
of smooth muscle–infiltrating mast cells in asthma, which 
is absent in EB.1 This is an excellent argument that confirms 
the notion that merely counting inflammatory cells may not 
necessarily indicate a role for such cells in a chronic inflam-
matory disease; cells playing an effector role must be found 
at the right place and time during the course of the disease. 
Interestingly, a similar mechanism has been found for the in-
duction of AHR by eosinophils. Several studies have shown 
that asthmatic airway tissue, unlike non-  asthmatic controls, 
is characterized by a preponderance of activated eosinophils, 
releasing MBP, around cholinergic nerve fibres.14,15 Following 
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systems has allowed a carefully planned reductionist approach 
toward understanding the role of specific factors in the immu-
nopathology of eosinophilic airway inflammation. The use of 
such models has shown that IL-  5-  dependent differentiation 
of eosinophils in the bone marrow and   eotaxin-  dependent 
recruitment of eosinophils to lung tissue are very important 
in the generation of eosinophilic airway inflammation.36
–40 
However, a definitive role for eosinophils could not be es-
tablished until Lee and colleagues developed an   eosinophil-   
deficient transgenic line of mice, the PHIL mouse, using a 
method involving the developmental ablation of eosinophil 
peroxidase–expressing progenitor cells through simultane-
ous activation of the diphtheria toxin A chain protein.41 Us-
ing this model, it was possible to show that the absence of 
eosinophils resulted in the abrogation of all of the pathophys-
iologic features of allergic airway inflammation, including 
ASM hyperreactivity and mucus hypersecretion. However, 
using this model, it was impossible to show whether the effect 
of eosinophils was dependent on the release of   granule-  stored 
proteins or other factors. A recent study from the same lab-
oratory further confirmed the role of eosinophils in severe 
asthma; using an   allergen-  free model that systemically ex-
presses IL-  5 in T cells and locally expresses   eotaxin-  2 in lung 
epithelial cells, the authors demonstrated that the specific re-
cruitment of eosinophils to the airways resulted in the devel-
opment of pathological lesions compatible with severe asthma 
in human.40 Thus, these studies showed that the eosinophil 
is sufficient for the genesis of the immunopathological de-
rangements seen in allergic airway inflammation and the ex-
pression of the pathophysiological changes associated with   
severe asthma.
In human studies, eosinophils have also been linked to 
tissue remodelling, a critical feature of asthma, even in young 
children. The cytokines thought to be involved, including   
IL-  4, IL-  13,42,43 and transforming growth factor β (TGF-  β),44 
as well as chemokines (eg, RANTES45) known to be produced 
by lymphocytes, are also synthesized, stored and released by 
eosinophils. These cells may also be involved in airway re-
modelling through tenascin production; indeed, using an 
  allergen-  induced cutaneous model of asthmatic inflamma-
tion, it was shown that the release of TGF-  β and IL-  13 by 
  eosinophils contributes to airway remodelling.46
Eosinophils and Immune Regulation
Recent studies have shown that eosinophils, in addition to 
their effector role, may play an immunoregulatory role in 
the immunopathogenesis of allergic asthma through interac-
tion with T cells. Eosinophils have been shown to influence 
the function of lymphocytes directly since they express co-
the positive control group were not hyperreactive,24 rendering 
the main outcome of airway hyperreactivity (AHR) impos-
sible to assess accurately. Subsequent studies showed simi-
lar disappointing results with this antibody, suggesting that 
eosinophils may not play a significant role in airway hyper-
responsiveness. There was also doubt whether the presence of 
eosinophils in sputum or airway fluids truly reflected those in 
the airway tissue. Indeed, Flood-  Page and colleagues showed 
that mepolizumab depleted less than 55% of bronchial tissue 
and bone marrow eosinophils while significantly diminish-
ing blood and BAL fluid eosinophils in treated subjects.25 
Whether this   explains the observed lack of effect of anti-  IL-  5 
on AHR remains to be fully addressed. It is interesting that 
Liu and colleagues later showed a marked reduction in the 
expression of messenger ribonucleic acid of the surface IL-  5   
receptor (mIL-  5Rα), as well as its intra  cellular component 
(mIL-  5Rβ), from BAL eosinophils in contrast to circulating 
blood eosinophils.26 Further, airway   eosinophils were shown 
not to release   eosinophil-  derived neurotoxin (EDN) when 
treated with IL-  5 compared with their blood counterparts. 
This suggests that the function (both survival and mediator 
release) of BAL eosinophils may be independent of IL-  5.27 
Recent studies have reported that the reduction in blood and 
sputum eosinophils in   mepolizumab-  treated subjects had an 
effective   steroid-  sparing effect in patients with EB with or 
without asthma.28
It is important to note that the development, matura-
tion, and survival of the eosinophil may occur in situ in tis-
sue inflammatory sites. It has been shown that eosinophil 
progenitors released into the circulation reach tissue sites29 
and can differentiate, in situ.30
–32 Furthermore, eosinophils 
store and release up to 30 different cytokines, chemokines, 
and growth factors,33
–35 which may further amplify the in-
flammatory milieu. As such, in situ production of various 
  eosinophil-  activating factors may be important in tissue eo-
sinophil reactions not involving IL-  5. More importantly, asso-
ciation studies are notoriously difficult in delineating the role 
of specific cells or factors in disease since such studies are car-
ried out in patients already diagnosed with asthma. Thus, the 
use of animal models has extended our understanding of the 
role of inflammatory cells in the pathophysiology of asthma.
Eosinophils Are Crucial in the Pathophysiology of 
Asthma: The PHIL Mouse Model
Mouse model sensitization to ovalbumin (OVA) via the in-
traperitoneal route, followed by intranasal challenge with the 
same protein, has been used to generate eosinophilic airway 
inflammation accompanied by AHR and other components 
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response in the mouse through direct activation of Toll-  like 
receptor 2 by EDN.60
Eosinophil as a Marker of Allergic Disease and 
Asthma Phenotyping
Atopic diseases such as asthma, dermatitis, and rhinitis are 
classically associated with increased tissue eosinophils.61 The 
presence of eosinophils has been correlated with disease se-
verity and bronchial hyperresponsiveness.62 Despite this as-
sociation, there is significant heterogeneity among subgroups 
in asthma and even within individual patients from season to 
season. Clearly, different inflammatory phenotypes are pres-
ent in asthmatics.63 For example, EB is characterized by an 
increase in airway eosinophils, yet in contrast to asthma, AHR 
does not appear to be a feature. This raises the question: Why 
is EB not associated with AHR if eosinophils contribute to 
AHR? In comparing mild asthma with EB, Brightling and col-
leagues found that although both groups had eosinophilia, the 
significant difference in the airway pathology of the asthma 
patient was the presence of mast cells within the smooth 
  muscle.2 This mast cell myositis was proposed as the cause of 
AHR in asthma, which suggested that AHR, a key feature of 
asthma, involves cells and mediators beyond the eosinophil.
Traditionally, mast cells are responsible for the acute 
phase of the asthmatic response via IgE-  mediated histamine 
release and smooth muscle stimulation. Mild asthma, by defi-
nition, can have AHR and acute periods of bronchospasm, 
often allergy related. In contrast, patients with mild asthma 
should not have decreased lung function by spirometry, nor 
should they show exacerbations requiring hospitalization.64 
Thus, it was important to note that in a subsequent article by 
many of the same authors interested in mast cell myositis, in 
moderate to severe asthmatics, management of eosinophils 
did make a difference in asthma symptoms and outcomes.65 
After a run-  in period in which they attempted to gain base-
line measurements of control with systemic and inhaled cor-
ticosteroids, patients with moderate to severe asthma were 
randomized to two groups. One group received standard but 
strict medical therapy based on the guidelines of the Brit-
ish Thoracic Society (BTS). The other group was managed 
by the same guidelines but with the addition of regular spu-
tum analyses of eosinophilia or nitric oxide (NO) produc-
tion. The sputum group was closely monitored for direct evi-
dence of eosinophil activity in the airway as a signal to adjust 
medication accordingly. Unlike the sputum group, the BTS 
group had only symptoms and lung function to guide ther-
apy, which are the end result of inflammatory damage. There 
was a very convincing improvement in the outcomes for the 
  eosinophil-  controlled group. Sputum eosinophil number and 
stimulatory molecules essential for interaction with lympho-
cytes47 and were shown, at least in mice, to transmigrate to 
and from lymphoid tissues and to present antigens to lym-
phocytes,48,49 albeit at a lower efficiency than that of profes-
sional   antigen-  presenting cells to naive T cells. This supports 
the notion that eosinophils can maintain and play a role in 
immune responses.
Four areas involving the role of the eosinophil in immune 
system regulation are worth emphasizing. The first relates 
to the fact that eosinophils naturally home to the thymus 
during infancy and in the absence of any identifiable “dan-
ger signal.”50,51 Thus, eosinophils may also be involved ear-
lier in the ontogeny of the immune response, as suggested 
by studies showing that thymus eosinophils are active par-
ticipants in MHC class I–restricted deletion of autoreactive 
T cells during the early neonatal period.52 Second, eosinophils 
synthesize, store, and release at least 30 different cytokines, 
chemokines, and growth factors with the potential to regu-
late the local (in situ) immune and inflammatory milieu in 
lymphoid  tissue.53  As  such,    eosinophil-  derived  cytokine 
production may directly influence T-  cell selection by den-
dritic cells and may, therefore, determine the choice between   
T-  cell tolerance or activation. TGF-  β, for which the eosino-
phil is a well-  acknowledged source,54 has also been related 
to T-  lymphocyte subset development.55 The specific recruit-
ment of eosinophils into lymphoid tissues puts these cells in 
a position to exert   immunomodulatory effects on T cells in 
  eosinophil-  associated diseases.
Third, the induction by   interferon-  γ (IFN-  γ) of indoleam-
ine 2,3-  dioxygenase (IDO), the rate-  limiting enzyme in the 
oxidative catabolism of tryptophan, may also be a significant 
and potent mechanism by which dendritic cells induce apop-
tosis and inhibit proliferation of T-  helper cells.56   Lymphoid-   
tissue eosinophils, either directly or indirectly, may induce 
T-  cell apoptosis through synthesis and release of IFN-  γ, fol-
lowing the ligation of CD28 on eosinophils57 and subsequent 
induction of IDO in dendritic cells. Our studies recently 
showed that eosinophils constitutively express IDO and in-
duce Th1 but not Th2 apoptosis.58 Eosinophils may, therefore, 
directly influence T-  cell function through tryptophan catab-
olism via eosinophil constitutive expression of biologically   
active IDO.
The fourth indication that eosinophils have the capacity to 
influence T-  cell regulation and its inflammatory and damag-
ing sequelae was reports showing that EDN, a cationic pro-
tein stored in the crystalloid granules of eosinophils, induced 
the migration and maturation of dendritic cells.59 Subsequent 
studies from the same authors demonstrated that intratra-
cheal instillation of OVA-  loaded dendritic cells pretreated 
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  present with the same clinical features of the disease or the 
same pathologic inflammatory profiles. All of this confirms 
the paradigm that asthma is a complex heterogeneous set of 
syndromes and that treating the multitude of changes occur-
ring in the asthmatic airways requires targeting the complex-
ity of the inflammatory cell phenotype environment with a 
view to reducing the clinical manifestation of the condition. 
We fully agree that conservative reductionist approaches have, 
hitherto, served us well in understanding the potential func-
tions of various cells and molecules but may not necessarily 
generate the best therapeutic options in a disease character-
ized by complex cellular and cytokine dyscrasia. Of note is the 
fact that the most effective asthma drugs to date, corticoste-
roids, target multiple cell types involved in the chronic in-
flammation that characterizes asthma. Our next major chal-
lenge is to begin thinking about how we target systems and 
make sense of the extraordinary amount of data obtained 
from the complex setting of multiple phenotypes of asthma 
and tissue and organ environment in an individualized fash-
ion, avoiding the current “shotgun” approach of therapeutic 
intervention. As well, it is likely that targeting a functional 
pathway common to all inflammatory cellular infiltrates in 
asthma may prove to be an excellent future strategy in asthma 
therapy. In this regard, a major bias of our laboratory pro-
poses that targeting specific elements involved in intracel-
lular mechanisms regulating exocytosis leading to mediator 
release, a common feature of all immune and inflammatory 
cells, may be an efficient path to pursue in this regard.
In conclusion, any attempt at ascribing a precise role 
for any given immune, inflammatory, or structural cell type 
in asthma will be constantly hampered by the recognition 
that asthma is not a single clinical entity and should, there-
fore, not be expected to be associated with or dependent on 
a single cell-  type function. One disease, one cell type, one 
molecule will never be a viable approach to such a complex 
condition. Instead, what is needed is a better and more ac-
curate phenotyping of asthma and a greater appreciation of 
  patient-  directed, rather than   disease-  directed, therapies. It is 
our firm conviction that complex diseases require complex 
therapeutic approaches.
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